[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569053":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":36,"locations":42,"responsibleParty":55,"collaborators":40,"id":58,"slug":40,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":40,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":40,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":44,"whyStopped":40,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Alexandria University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"group E","ACTIVE_COMPARATOR","81 patients will receive subcutaneous enoxaparin 40 mg every 24 hours starting 12 hours after bariatric surgery for 14 days.",[13],"Drug: Enoxaparin",{"label":15,"type":16,"description":17,"interventionNames":18},"group R","EXPERIMENTAL","81 patients will receive oral rivaroxaban 10 mg once daily starting 24 hours after bariatric surgery for 14 days.",[19],"Drug: rivaroxaban",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Enoxaparin","40mg",[9],[9],{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"rivaroxaban","10mg",[15],[15],[33],{"name":34,"affiliation":5,"role":35},"sarah m elgamal, MD","PRINCIPAL_INVESTIGATOR",[37],{"name":34,"role":38,"phone":39,"phoneExt":40,"email":41},"CONTACT","01005496440",null,"sarahelgamal1990@yahoo.com",[43],{"facility":5,"status":44,"city":45,"state":40,"zip":40,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Alexandria","Egypt",{"type":48,"coordinates":49},"Point",[50,51],29.91582,31.20176,{"lat":51,"lon":50},[54],{"name":34,"role":38,"phone":39,"phoneExt":40,"email":41},{"type":35,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"sarah mohamed","Lecturer anesthesia and intensive care","100569053",false,"NCT06689241","Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery","Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Morbidly Obese Patients Undergoing Bariatric Surgery: An open_label Randomized Controlled Trial","Inclusion Criteria:\n\n* Age: 20-60 years, both sexes.\n* ASA physical status class I to III.\n* BMI 35-50 kg\u002Fm²\n\nExclusion Criteria:\n\n* Severe cardiac disorder\n* chronic renal failure\n* liver cirrhosis\n* major psychological disorder",true,"ALL","20 Years","60 Years",{"count":69,"type":70},162,"ESTIMATED","INTERVENTIONAL",[73],"NA","Rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism in morbidly obese patients undergoing bariatric surgery: An open\\_label randomized controlled trial",[76,77],"Morbid Obesity","Bariatric Surgery Candidate",[79,80,28],"venous thromboembolism","enoxaparin","2025-04-17",{"date":83,"type":84},"2025-04-22","ACTUAL",{"date":86,"type":84},"2024-10-01",{"date":88,"type":70},"2026-05-01",{"name":5,"class":6},1]